Monoclonal antibodies can either target the receptors overexpressed on tumor cells (such as HER2, EGFR, VEGFR, etc.)or target their ligands to neutralize those receptors on the cell surface (such as bevacizumab for VEGF). The gene discussed is ERBB2; the disease is neoplasm.